Follow
About John
John Vandermosten is currently a senior biotechnology research analyst for Zacks Investment Research where he covers a portfolio of small-cap biotechnology names. His background includes 17 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. Formerly, Mr. Vandermosten was a research analyst for Singular Research covering the healthcare space and a consultant with Coker Group, a national healthcare services firm providing financial advisory, investment banking, healthcare IT, and other services to hospitals and other health care organizations.
John's Videos
John Vandermosten talks about the expansion of gene therapy and how it is used to combat auto-immune diseases.
John Vandermosten
BIOTECHNOLOGY
4:36
John Vandermosten digs into the biotechnology sector. Learn the smoking cessation drugs likely to create value for biotech stocks.
John Vandermosten
BIOTECHNOLOGY
7:11
At MoneyShow, John Vandermosten of Zacks Investment Research: one area big in cancer drugs has been checkpoint inhibitors, like Keytruda from Merck. They work well in about 20% of people.
John Vandermosten
STOCKS
7:49